Printer Friendly

GHIF announces sale of MDGH's Priority Review Voucher (PRV).

M2 EQUITYBITES-May 8, 2019-GHIF announces sale of MDGH's Priority Review Voucher (PRV)

(C)2019 M2 COMMUNICATIONS http://www.m2.com

The Global Health Investment Fund (GHIF) reported on Tuesday the sale of Medicines Development for Global Health's (MDGH) Priority Review Voucher (PRV) following the US Food & Drug Administration (FDA) approval of moxidectin for river blindness (onchocerciasis), a debilitating disease in low-income countries.

Headquartered in Melbourne, Australia, MDGH's moxidectin, an oral treatment, is the first new US FDA-approved treatment for river blindness in the last 20 years.

Since 2015, GHIF has provided USD13m to support MDGH's efforts to complete clinical studies, manufacture moxidectin as well as conduct the US FDA's registration process. Under a Global Access Agreement, significant proceeds will go towards additional research on moxidectin as well as its deployment in key underserved markets at risk for river blindness.

The FDA's neglected tropical disease PRV program is designed to encourage the development of drugs and treatments for rare and neglected diseases. Upon approval of a new treatment for a listed neglected disease, the developer receives a voucher to receive a priority review for another product from the FDA. This priority review shortens the review of a new drug application to six months rather from ten or more. The voucher can be sold, without restrictions, to third parties.

GHIF, a social impact investment fund structured by JPMorgan Chase & Co and the Bill & Melinda Gates Foundation, finances the development of drugs, vaccines, devices and diagnostics for diseases that disproportionately burden low-income populations.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:May 8, 2019
Words:261
Previous Article:Main Street declares 7.9% higher dividend of USD0.205 per share per month for Q3 2019.
Next Article:Leggett declares 5.3% higher dividend of USD0.40 per share for Q2 2019 year over year.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters